Display options
Cite
West AC, Christiansen AJ, Smyth MJ, et al. The combination of histone deacetylase inhibitors with immune-stimulating antibodies has potent anti-cancer effects. Oncoimmunology. 2012;1(3):377-379doi: 10.4161/onci.18804.
West, A. C., Christiansen, A. J., Smyth, M. J., & Johnstone, R. W. (2012). The combination of histone deacetylase inhibitors with immune-stimulating antibodies has potent anti-cancer effects. Oncoimmunology, 1(3), 377-379. https://doi.org/10.4161/onci.18804
West, Alison C, et al. "The combination of histone deacetylase inhibitors with immune-stimulating antibodies has potent anti-cancer effects." Oncoimmunology vol. 1,3 (2012): 377-379. doi: https://doi.org/10.4161/onci.18804
West AC, Christiansen AJ, Smyth MJ, Johnstone RW. The combination of histone deacetylase inhibitors with immune-stimulating antibodies has potent anti-cancer effects. Oncoimmunology. 2012 May 01;1(3):377-379. doi: 10.4161/onci.18804. PMID: 22737621; PMCID: PMC3382866.
Copy Download .nbib Format: NLM
Share it on

Oncoimmunology. 2012 May 01;1(3):377-379. doi: 10.4161/onci.18804.

The combination of histone deacetylase inhibitors with immune-stimulating antibodies has potent anti-cancer effects.

Oncoimmunology

Alison C West, Ailsa J Christiansen, Mark J Smyth, Ricky W Johnstone

Affiliations

  1. Cancer Therapeutics; The Peter MacCallum Cancer Centre; East Melbourne, Australia ; Cancer Immunology Program; The Peter MacCallum Cancer Centre; East Melbourne, Australia.

PMID: 22737621 PMCID: PMC3382866 DOI: 10.4161/onci.18804

Abstract

The use of immunotherapy to treat cancer is rapidly gaining momentum. Using pre-clinical mouse models, we have recently demonstrated potent and long lasting tumor regression can be elicited by immune-stimulating monoclonal antibodies (mAbs) when combined with histone deacetylase inhibitors (HDACi) and believe this therapy will have broad application in humans.

References

  1. Blood. 2009 Jul 9;114(2):380-93 - PubMed
  2. Nat Rev Drug Discov. 2006 Sep;5(9):769-84 - PubMed
  3. Proc Natl Acad Sci U S A. 2011 Mar 8;108(10):4141-6 - PubMed
  4. Nat Med. 2006 Jun;12(6):693-8 - PubMed
  5. Apoptosis. 2009 Apr;14(4):364-75 - PubMed
  6. Proc Natl Acad Sci U S A. 2007 May 8;104(19):8071-6 - PubMed
  7. Cancer Chemother Pharmacol. 2010 Aug;66(3):611-6 - PubMed
  8. Immunology. 2008 Feb;123(2):218-27 - PubMed
  9. Cancer Lett. 2009 Aug 8;280(2):125-33 - PubMed
  10. Cancer Immunol Immunother. 2008 May;57(5):647-54 - PubMed

Publication Types